Rx Medicare

Baxter International Inc. (NYSE: BAX) confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union. Baxter continues to deliver vaccine to national public health authorities that have agreements with the company.

Read More…

Related Posts

• Baxter Receives EMEA Positive Opinion For CELVAPAN H1N1 Pandemic Influenza Vaccine
• CSL Biotherapies Obtains FDA Licensure For Use Of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine In Children
• Practice Fusion Identifies 300,000 High-Risk Patients For H1N1 Influenza Vaccine, In-line With CDC Pandemic Guidelines
• European Medicines Agency Recommends Authorisation Of Two Vaccines For Influenza Pandemic (H1N1) 2009
• Medicago Receives Regulatory Approval To Begin Human Clinical Testing With Its Avian Flu Pandemic Vaccine
• Diagnostic Hybrids Receives FDA Emergency Use Authorization For D3 Ultra 2009 H1N1 Influenza A Virus ID Kit
• European Medicines Agency Updates On Pandemic Influenza
• VaxInnate Licenses Recombinant H1N1 Pandemic Swine Flu Vaccine To Biological E.; Vaccine Could Become Available For Use In India This Year
• Statement By The Welsh Assembly Government On Latest Developments In Respect Of The Influenza A (H1N1) Swine Flu Pandemic
• As Influenza Cases Rise In Europe, Experts Urge Uptake Of H1N1 Vaccine
• FDA Approves Additional Vaccine For 2009 H1N1 Influenza Virus
• Get Smart About Swine Flu H1N1 Swine Flu Vaccine Influenza P
• Health Canada Approves Pandemic H1N1 Flu Vaccine For Canadians
• MANUFACTURING THE H1N1 FLU VACCINE NASAL SPRAY Influenza
• USDA Conducting Confirmatory Testing On Possible Detection Of 2009 Pandemic H1N1 Influenza In U.S. Swine

Tags: approval, baxter, celvapan, commission, efficacy, european, h1n1, influenza, pandemic, receives, vaccine

This entry was posted on Sunday, October 11th, 2009 at 8:10 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.